At the time of writing, Arvinas Inc. [ARVN] stock is trading at $24.00, up 0.97%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ARVN shares have gain 3.45% over the last week, with a monthly amount drifted -11.18%, and not seem to be holding up well over a long-time horizon.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
On 8, May 2023, Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. In a post published today on Yahoo Finance, Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) protein degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer. Four posters will be presented during the poster session at the annual congress, which will be held from May 11-13, 2023, in Berlin, Germany.
From an analyst’s perspective:
For the past year, the stock price of Arvinas Inc. fluctuated between $22.00 and $58.58. Arvinas Inc. [NASDAQ: ARVN] shares were valued at $24.00 at the most recent close of the market.
Analyzing the ARVN fundamentals
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.37 points at the first support level, and at 22.74 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.33, and for the 2nd resistance point, it is at 24.66.
Arvinas Inc. [ARVN] reported earnings per share of -$1.54 for its fiscal quarter that ended on 3/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$1.51/share, meaning a difference of -$0.03 and a surprise factor of -2.00%. By comparison, the stated earnings for the previous quarter ended on 12/30/2022 were -$1.56 per share as compared to estimates of -$1.22 per share, a difference of -$0.34 representing a surprise of -27.90%.
Ratios To Look Out For
It is important to note that Arvinas Inc. [NASDAQ:ARVN] has a current ratio of 4.10.
Transactions by insiders
Insider trading, which has resulted in 3 insider purchases of 24,986 shares and 3 insider sales of 8,674 shares in the past three months, is now the topic of our analysis. Recent insider trading involved Houston John G, President and CEO, that happened on Mar 01 when 5878.0 shares were sold. Chief Financial Officer, Cassidy Sean A completed a deal on Mar 01 to sell 1745.0 shares. Meanwhile, Chief Scientific Officer Taylor Ian sold 1051.0 shares on Mar 01.